Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg

RationaleAlprazolam extended-release (XR) is approved for the treatment of panic disorder. This sustained formulation is absorbed in a delayed manner and is therefore expected to produce fewer and less severe side effects than its immediate release equivalent (alprazolam IR). The effect of alprazolam XR on potentially dangerous daily activities, such as driving a car, is expected to be less as compared to alprazolam IR.ObjectivesThe present study was designed to compare the effects of alprazolam XR (1 mg) and alprazolam IR (1 mg) on actual driving ability and cognitive function.MethodEighteen healthy volunteers (aged 20–45 years) participated in a double-blind, placebo-controlled, three-way crossover study. At 4 h post-dose, subjects performed a standardized driving test on a primary highway in normal traffic. Cognitive and psychomotor tests were assessed 1, 2.5, and 5.5 h post-dose. Memory functioning was measured only 1 h after administration.ResultsBoth formulations severely impaired driving performance between 4 and 5 h after administration. The magnitude of impairment in the driving test observed with alprazolam XR was about half that observed with alprazolam IR. Laboratory test results were in line with the driving data.ConclusionsThe acute impairing effects of alprazolam XR 1 mg on driving and psychomotor functions were generally less, as compared to its immediate-release equivalent, but still of sufficient magnitude to increase the risk of becoming involved in traffic accidents.

[1]  R. Griffiths,et al.  Alprazolam absorption kinetics affects abuse liability * , 1995, Clinical pharmacology and therapeutics.

[2]  David J Roberts.  Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  Jan Uillem Louuerens.  THE RELATIONSHIP BETWEEN DRIVERS' BLOOD ALCOHOL CONCENTRATION CBAC) AND ACTUAL DRIVING PERFORMANCE DURING HIGH SPEED TRAVEL. , 1987 .

[4]  I. Hindmarch,et al.  Alprazolam and lorazepam single and multiple-dose effects on psychomotor skills and sleep , 2004, European Journal of Clinical Pharmacology.

[5]  J. O'hanlon,et al.  Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers , 1995, European Neuropsychopharmacology.

[6]  I. Neutel,et al.  Benzodiazepine‐related traffic accidents in young and elderly drivers , 1998 .

[7]  D. Greenblatt,et al.  The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state , 1992, European Journal of Clinical Pharmacology.

[8]  P. Kroboth,et al.  Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration , 2004, Psychopharmacology.

[9]  E. Volkerts,et al.  Therapeutic Effects and Effects on Actual Driving Performance of Chronically Administered Buspirone and Diazepam in Anxious Outpatients , 1992, Journal of clinical psychopharmacology.

[10]  Herbert Moskowitz,et al.  Laboratory studies of the effects of alcohol on some variables related to driving. , 1973 .

[11]  D. Greenblatt,et al.  Comparative single‐dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo , 1988, Clinical pharmacology and therapeutics.

[12]  D. Greenblatt,et al.  A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. , 2000, Journal of clinical psychopharmacology.

[13]  W. Riedel,et al.  Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. , 2002, Sleep.

[14]  P. Glue,et al.  Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers , 2006, American journal of therapeutics.

[15]  J. Ramaekers,et al.  Acute Effects of 3,4-Methylenedioxymethamphetamine (MDMA) on Behavioral Measures of Impulsivity: Alone and in Combination with Alcohol , 2006, Neuropsychopharmacology.

[16]  G. Moroz.  High-potency benzodiazepines: recent clinical results. , 2004, The Journal of clinical psychiatry.

[17]  Joris C Verster,et al.  Effects of Alprazolam on Driving Ability, Memory Functioning and Psychomotor Performance: A Randomized, Placebo-controlled Study , 2002, Neuropsychopharmacology.

[18]  K. Rickels.  Alprazolam extended-release in panic disorder , 2004, Expert opinion on pharmacotherapy.

[19]  J. O'hanlon,et al.  Driving performance under the influence of drugs: rationale for, and application of, a new test. , 1984, British journal of clinical pharmacology.

[20]  J. Ramaekers.  Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. , 2003, The Journal of clinical psychiatry.

[21]  M. Fillmore,et al.  Acute effects of oral cocaine on inhibitory control of behavior in humans. , 2002, Drug and alcohol dependence.

[22]  N. Muntjewerff,et al.  Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests , 1995, Psychopharmacology.

[23]  J. Verster,et al.  Is it Safe to Drive a Car when Treated with Anxiolytics? Evidence from onthe- Road Driving Studies During Normal Traffic , 2005 .

[24]  G. Logan.  On the ability to inhibit thought and action , 1984 .

[25]  J. O'hanlon,et al.  Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. , 1999, Journal of clinical psychopharmacology.

[26]  M. Eller,et al.  Absence of effect of food on alprazolam absorption from sustained release tablets. , 1990, Biopharmaceutics & drug disposition.

[27]  J F O'Hanlon,et al.  Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies. , 1995, Neuropsychobiology.

[28]  R. F. Borkenstein,et al.  The role of the drinking driver in traffic accidents (the Grand Rapids study) , 1974 .

[29]  T. Carr,et al.  Inhibitory Processes in Attention, Memory and Language , 1994 .

[30]  C. Kilts,et al.  Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam , 2004, Psychopharmacology.

[31]  J. Sweeney,et al.  Do Alprazolam‐Induced Changes in Saccadic Eye Movement and Psychomotor Function Follow the Same Time Course? , 1998, Journal of clinical pharmacology.

[32]  F. Salek,et al.  Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  C. I. Neutel,et al.  Risk of traffic accident injury after a prescription for a benzodiazepine. , 1995, Annals of epidemiology.

[34]  P. Kroboth,et al.  Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects , 2005, Psychopharmacology.

[35]  J F O'Hanlon,et al.  Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989‐94 , 1995, Allergy.

[36]  P. Rubé,et al.  L’examen Clinique en Psychologie , 1959 .

[37]  T. MacDonald,et al.  Association of road-traffic accidents with benzodiazepine use , 1998, The Lancet.

[38]  M. Eller,et al.  Pharmacokinetics and Pharmacodynamics of Alprazolam Following Single and Multiple Oral Doses of a Sustained‐Release Formulation , 1989, Journal of clinical pharmacology.

[39]  D. Sibbritt,et al.  Alprazolam is relatively more toxic than other benzodiazepines in overdose. , 2004, British journal of clinical pharmacology.

[40]  H. Curran.  Tranquillising memories: A review of the effects of benzodiazepines on human memory , 1986, Biological Psychology.

[41]  P. Rosenzweig,et al.  Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers , 2007, European Journal of Clinical Pharmacology.

[42]  J. Verster,et al.  Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. , 2006, CNS drug reviews.

[43]  David J. Greenblatt,et al.  Clinical Pharmacokinetics of Alprazolam , 1993, Clinical pharmacokinetics.